AKBA
Akebia Therapeutics, Inc.
Biotechnology
Market Cap$317M
5Y Perf.-89.9%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
AKBA vs PTGX vs FOLD vs PRTA
Revenue, margins, valuation, and 5-year total return — side by side.
PTGX
Protagonist Therapeutics, Inc.
Biotechnology
Market Cap$6.36B
5Y Perf.+498.0%
FOLD
Amicus Therapeutics, Inc.
Biotechnology
Market Cap$4.55B
5Y Perf.+15.9%
PRTA
Prothena Corporation plc
Biotechnology
Market Cap$567M
5Y Perf.-1.2%
AKBA vs PTGX vs FOLD vs PRTA — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | AKBA | PTGX | FOLD | PRTA |
|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Biotechnology | Biotechnology |
| Market Cap | $317M | $6.36B | $4.55B | $567M |
| Revenue (TTM) | $232M | $18M | $634M | $58M |
| Net Income (TTM) | $-21M | $-115M | $-27M | $-151M |
| Gross Margin | 81.0% | 100.0% | 87.9% | -39.7% |
| Operating Margin | 2.3% | -8.1% | 5.2% | -210.6% |
| Forward P/E | — | 30.6x | 40.6x | 42.7x |
| Total Debt | $216M | $10M | $483M | $14M |
| Cash & Equiv. | $185M | $128M | $214M | $308M |
AKBA vs PTGX vs FOLD vs PRTA — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
AKBA
PTGX
FOLD
PRTA
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Akebia Therapeutics… (AKBA) | 100 | 10.1 | -89.9% |
| Protagonist Therape… (PTGX) | 100 | 598.0 | +498.0% |
| Amicus Therapeutics… (FOLD) | 100 | 115.9 | +15.9% |
| Prothena Corporatio… (PRTA) | 100 | 98.8 | -1.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: AKBA vs PTGX vs FOLD vs PRTA
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: FOLD leads in 3 of 7 categories, making it the strongest pick for profitability and margin quality and recent price momentum and sentiment. Protagonist Therapeutics, Inc. is the stronger pick specifically for valuation and capital efficiency and capital preservation and lower volatility. AKBA also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
AKBA
Akebia Therapeutics, Inc.
The Growth Play
AKBA is the clearest fit if your priority is growth exposure.
- Rev growth 47.5%, EPS growth 93.7%, 3Y rev CAGR -6.9%
- 47.5% revenue growth vs PRTA's -92.8%
Best for: growth exposure
PTGX
Protagonist Therapeutics, Inc.
The Income Pick
PTGX is the #2 pick in this set and the best alternative if income & stability and long-term compounding is your priority.
- beta 0.25
- 7.4% 10Y total return vs FOLD's 119.2%
- Lower volatility, beta 0.25, Low D/E 1.7%, current ratio 12.71x
- Beta 0.25, current ratio 12.71x
Best for: income & stability and long-term compounding
FOLD
Amicus Therapeutics, Inc.
The Quality Compounder
FOLD carries the broadest edge in this set and is the clearest fit for quality and momentum.
- -4.3% margin vs PTGX's -6.5%
- +137.9% vs AKBA's -52.0%
- -3.2% ROA vs PRTA's -42.3%, ROIC 5.3% vs -21.0%
Best for: quality and momentum
PRTA
Prothena Corporation plc
The Secondary Option
PRTA lags the leaders in this set but could rank higher in a more targeted comparison.
Best for: healthcare exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | AKBA | 47.5% revenue growth vs PRTA's -92.8% |
| Value | PTGX | Lower P/E (30.6x vs 42.7x) |
| Quality / Margins | FOLD | -4.3% margin vs PTGX's -6.5% |
| Stability / Safety | PTGX | Beta 0.25 vs AKBA's 1.14, lower leverage |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | FOLD | +137.9% vs AKBA's -52.0% |
| Efficiency (ROA) | FOLD | -3.2% ROA vs PRTA's -42.3%, ROIC 5.3% vs -21.0% |
AKBA vs PTGX vs FOLD vs PRTA — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
FY 2024
Segment breakdown not available.
FY 2025
AKBA vs PTGX vs FOLD vs PRTA — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLAKBALAGGINGPRTA
Who Leads Where
AKBA leads in 1 of 6 categories
PTGX leads 1 • FOLD leads 0 • PRTA leads 0 • 3 tied
Explore the data ↓PRTAProthena Corporation …
0leads
FOLDAmicus Therapeutics, …
0leads
PTGXProtagonist Therapeut…
1leads
AKBAAkebia Therapeutics, …
1leads
6 Total Categories
CATEGORYLEADERvs PTGXvs FOLDMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
Tied
—
Valuation MetricsMultiples, price ratios, and targets
AKBA3/6
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
Tied
—
Total Returns1Y, 3Y, 5Y total returns with dividends
PTGX4/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
Evenly matched — FOLD and PRTA each lead in 2 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
FOLD is the larger business by revenue, generating $634M annually — 35.8x PTGX's $18M. Profitability is closely matched — net margins range from -4.3% (FOLD) to -6.5% (PTGX). On growth, PRTA holds the edge at +17.1% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | AKBAAkebia Therapeuti… | PTGXProtagonist Thera… | FOLDAmicus Therapeuti… | PRTAProthena Corporat… |
|---|---|---|---|---|
| RevenueTrailing 12 months | $232M | $18M | $634M | $58M |
| EBITDAEarnings before interest/tax | $6M | -$141M | $40M | -$121M |
| Net IncomeAfter-tax profit | -$21M | -$115M | -$27M | -$151M |
| Free Cash FlowCash after capex | $60M | -$116M | $30M | -$85M |
| Gross MarginGross profit ÷ Revenue | +81.0% | +100.0% | +87.9% | -39.7% |
| Operating MarginEBIT ÷ Revenue | +2.3% | -8.1% | +5.2% | -2.1% |
| Net MarginNet income ÷ Revenue | -8.8% | -6.5% | -4.3% | -2.6% |
| FCF MarginFCF ÷ Revenue | +25.8% | -6.6% | +4.7% | -147.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | -6.6% | -100.0% | +23.7% | +17.1% |
| EPS Growth (YoY)Latest quarter vs prior year | -2.2% | +126.3% | -89.0% | +153.6% |
Evenly matched — FOLD and PRTA each lead in 2 of 6 comparable metrics.
Valuation Metrics
AKBA leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
On an enterprise value basis, AKBA's 14.0x EV/EBITDA is more attractive than FOLD's 114.9x.
| Metric | AKBAAkebia Therapeuti… | PTGXProtagonist Thera… | FOLDAmicus Therapeuti… | PRTAProthena Corporat… |
|---|---|---|---|---|
| Market CapShares × price | $317M | $6.4B | $4.5B | $567M |
| Enterprise ValueMkt cap + debt − cash | $348M | $6.2B | $4.8B | $273M |
| Trailing P/EPrice ÷ TTM EPS | -56.73x | -48.22x | -164.85x | -2.32x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 30.60x | 40.62x | 42.68x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | 14.05x | — | 114.88x | — |
| Price / SalesMarket cap ÷ Revenue | 1.34x | 138.15x | 7.17x | 58.54x |
| Price / BookPrice ÷ Book value/share | 9.31x | 10.22x | 16.29x | 2.02x |
| Price / FCFMarket cap ÷ FCF | 4.66x | 113.36x | 152.43x | — |
AKBA leads this category, winning 3 of 6 comparable metrics.
Profitability & Efficiency
Evenly matched — AKBA and FOLD each lead in 3 of 9 comparable metrics.
Profitability & Efficiency
FOLD delivers a -12.0% return on equity — every $100 of shareholder capital generates $-12 in annual profit, vs $-63 for AKBA. PTGX carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to AKBA's 6.63x. On the Piotroski fundamental quality scale (0–9), AKBA scores 5/9 vs PRTA's 1/9, reflecting solid financial health.
| Metric | AKBAAkebia Therapeuti… | PTGXProtagonist Thera… | FOLDAmicus Therapeuti… | PRTAProthena Corporat… |
|---|---|---|---|---|
| ROE (TTM)Return on equity | -62.7% | -17.8% | -12.0% | -49.9% |
| ROA (TTM)Return on assets | -5.7% | -16.5% | -3.2% | -42.3% |
| ROICReturn on invested capital | +23.2% | -21.8% | +5.3% | -21.0% |
| ROCEReturn on capital employed | +13.3% | -23.9% | +5.1% | -47.0% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 4 | 4 | 1 |
| Debt / EquityFinancial leverage | 6.63x | 0.02x | 1.76x | 0.05x |
| Net DebtTotal debt minus cash | $31M | -$118M | $269M | -$294M |
| Cash & Equiv.Liquid assets | $185M | $128M | $214M | $308M |
| Total DebtShort + long-term debt | $216M | $10M | $483M | $14M |
| Interest CoverageEBIT ÷ Interest expense | 0.56x | — | 1.00x | — |
Evenly matched — AKBA and FOLD each lead in 3 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
PTGX leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in PTGX five years ago would be worth $33,876 today (with dividends reinvested), compared to $3,782 for AKBA. Over the past 12 months, FOLD leads with a +137.9% total return vs AKBA's -52.0%. The 3-year compound annual growth rate (CAGR) favors PTGX at 58.3% vs PRTA's -48.5% — a key indicator of consistent wealth creation.
| Metric | AKBAAkebia Therapeuti… | PTGXProtagonist Thera… | FOLDAmicus Therapeuti… | PRTAProthena Corporat… |
|---|---|---|---|---|
| YTD ReturnYear-to-date | -23.9% | +13.4% | +1.5% | +14.5% |
| 1-Year ReturnPast 12 months | -52.0% | +129.4% | +137.9% | +44.4% |
| 3-Year ReturnCumulative with dividends | +11.3% | +296.5% | +19.0% | -86.3% |
| 5-Year ReturnCumulative with dividends | -62.2% | +238.8% | +48.6% | -57.2% |
| 10-Year ReturnCumulative with dividends | -85.7% | +744.9% | +119.2% | -73.0% |
| CAGR (3Y)Annualised 3-year return | +3.6% | +58.3% | +6.0% | -48.5% |
PTGX leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
Evenly matched — PTGX and FOLD each lead in 1 of 2 comparable metrics.
Risk & Volatility
PTGX is the less volatile stock with a 0.25 beta — it tends to amplify market swings less than AKBA's 1.14 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. FOLD currently trades 99.9% from its 52-week high vs AKBA's 28.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | AKBAAkebia Therapeuti… | PTGXProtagonist Thera… | FOLDAmicus Therapeuti… | PRTAProthena Corporat… |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.14x | 0.25x | 0.63x | 0.96x |
| 52-Week HighHighest price in past year | $4.08 | $107.84 | $14.50 | $11.69 |
| 52-Week LowLowest price in past year | $1.13 | $41.29 | $5.51 | $4.32 |
| % of 52W HighCurrent price vs 52-week peak | +28.9% | +91.7% | +99.9% | +90.1% |
| RSI (14)Momentum oscillator 0–100 | 55.9 | 56.4 | 72.2 | 60.3 |
| Avg Volume (50D)Average daily shares traded | 2.8M | 752K | 3.0M | 474K |
Evenly matched — PTGX and FOLD each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: AKBA as "Buy", PTGX as "Buy", FOLD as "Buy", PRTA as "Buy". Consensus price targets imply 239.0% upside for AKBA (target: $4) vs 0.1% for FOLD (target: $15).
| Metric | AKBAAkebia Therapeuti… | PTGXProtagonist Thera… | FOLDAmicus Therapeuti… | PRTAProthena Corporat… |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $4.00 | $116.75 | $14.50 | $19.00 |
| # AnalystsCovering analysts | 11 | 26 | 24 | 28 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
AKBA leads in 1 of 6 categories (Valuation Metrics). PTGX leads in 1 (Total Returns). 3 tied.
Best OverallAkebia Therapeutics, Inc. (AKBA)Leads 1 of 6 categories
Loading custom metrics...
AKBA vs PTGX vs FOLD vs PRTA: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is AKBA or PTGX or FOLD or PRTA a better buy right now?
For growth investors, Akebia Therapeutics, Inc.
(AKBA) is the stronger pick with 47. 5% revenue growth year-over-year, versus -92. 8% for Prothena Corporation plc (PRTA). Analysts rate Akebia Therapeutics, Inc. (AKBA) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — AKBA or PTGX or FOLD or PRTA?
Over the past 5 years, Protagonist Therapeutics, Inc.
(PTGX) delivered a total return of +238. 8%, compared to -62. 2% for Akebia Therapeutics, Inc. (AKBA). Over 10 years, the gap is even starker: PTGX returned +744. 9% versus AKBA's -85. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — AKBA or PTGX or FOLD or PRTA?
By beta (market sensitivity over 5 years), Protagonist Therapeutics, Inc.
(PTGX) is the lower-risk stock at 0. 25β versus Akebia Therapeutics, Inc. 's 1. 14β — meaning AKBA is approximately 354% more volatile than PTGX relative to the S&P 500. On balance sheet safety, Protagonist Therapeutics, Inc. (PTGX) carries a lower debt/equity ratio of 2% versus 7% for Akebia Therapeutics, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — AKBA or PTGX or FOLD or PRTA?
By revenue growth (latest reported year), Akebia Therapeutics, Inc.
(AKBA) is pulling ahead at 47. 5% versus -92. 8% for Prothena Corporation plc (PRTA). On earnings-per-share growth, the picture is similar: Akebia Therapeutics, Inc. grew EPS 93. 7% year-over-year, compared to -148. 5% for Protagonist Therapeutics, Inc.. Over a 3-year CAGR, FOLD leads at 24. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — AKBA or PTGX or FOLD or PRTA?
Akebia Therapeutics, Inc.
(AKBA) is the more profitable company, earning -2. 3% net margin versus -25. 2% for Prothena Corporation plc — meaning it keeps -2. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AKBA leads at 9. 9% versus -1905. 8% for PRTA. At the gross margin level — before operating expenses — PTGX leads at 97. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is AKBA or PTGX or FOLD or PRTA more undervalued right now?
On forward earnings alone, Protagonist Therapeutics, Inc.
(PTGX) trades at 30. 6x forward P/E versus 42. 7x for Prothena Corporation plc — 12. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for AKBA: 239. 0% to $4. 00.
07Which pays a better dividend — AKBA or PTGX or FOLD or PRTA?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is AKBA or PTGX or FOLD or PRTA better for a retirement portfolio?
For long-horizon retirement investors, Protagonist Therapeutics, Inc.
(PTGX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 25), +744. 9% 10Y return). Both have compounded well over 10 years (PTGX: +744. 9%, AKBA: -85. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between AKBA and PTGX and FOLD and PRTA?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: AKBA is a small-cap high-growth stock; PTGX is a small-cap quality compounder stock; FOLD is a small-cap high-growth stock; PRTA is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
Revenue Growth>
%
(AKBA: -6.6% · PTGX: -100.0%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.